Edesa Biotech is trading 5.4% down at $2.62, with no verified catalyst directly explaining the decline. - The latest identified company news was October 15 FDA clearance for a Phase 2 vitiligo study; it does not explain the decline. - October 23 executive salary increases have not been linked in available reporting to the October 26 move. - The broader market is higher in the supplied context and does not explain the decline.